Incretins improve symptoms in obese HFpEF. Are they heart failure drugs?
The debate
7 clinicians quoted on the record
Trials in obese HFpEF improved symptoms and cut heart failure events, so start one as HF therapy.
Continue standard HFpEF therapy first. Add an incretin when obesity or diabetes is itself a treatment target.
Where the experts land
0–0 on record · 7 unplaced
Start an incretin as heart failure therapy · 0
On the record, unplaced · 7
Use incretins for obesity, not as core HF therapy · 0
“In the end, SUMMIT is not close to changing treatment norms in patients with HFpEF. As evidence-based clinicians, we should demand more from our partners in industry and academia.”
Who we found publicly on the record — a snapshot, not a poll of the field. Larger dots are deciders; dashed dots are scan-reported, not yet verified.
Where the field stands
Common ground
In obesity-related HFpEF, these drugs improve symptoms and quality of life alongside usual care.
The crux
Is this a heart failure drug, or just an obesity drug?
Still unknown
Guidance clarifying which phenotypes warrant them as heart failure therapy, reflecting the newest event-reduction data.
On the record
Their own words — position stated as published
Weight loss adjunct only
“When we think about optimal medical therapy in HFpEF, everybody should be on an SGLT2 inhibitor and an MRA, ideally nonsteroidal. Then you think about individualizing therapy to the patient sitting in front of you.”
Michelle M. Kittleson · Chair · X ↗
Start tirzepatide or semaglutide
“This is the first trial to demonstrate that a medication can change the clinical trajectory of the disease in patients with HFpEF and obesity. We think that these drugs are all compatible with each other and likely to be added in.”
Milton Packer · Principal investigator · X ↗
Weight loss adjunct only
“In the end, SUMMIT is not close to changing treatment norms in patients with HFpEF. As evidence-based clinicians, we should demand more from our partners in industry and academia.”
John M. Mandrola · Cardiac electrophysiologist · X ↗
Start tirzepatide or semaglutide
“Yes. We have seen two large study programs that enrolled patients with heart failure and preserved pump function (ie, HFpEF). Both trials documented a clear symptomatic benefit for patients. The effect of GLP‑1 receptor agonists appears to be additive to that of SGLT2 inhibitors.”
Ulrich Laufs · Professor and Chief of Cardiology · X ↗
Where do you land?
No votes yet — the measured split appears at 10.
Where the evidence stands
What's settled
2What's still open
1How this gets settled
Resolving trial — not yet identified
Who could settle it
Know an expert who could settle this? Suggest one →
Who this affects
Sources & verification
+ 27 more, each dated and verification-tagged